Immunis.AI Reports Results of a Prospective Study of its RNAseq-Based Liquid Biopsy in Early-Stage Prostate CancerJoel Wolter2021-10-12T12:59:23-04:00October 11, 2021|Read More
Immunis.AI Chosen by Amazon Web Services to Showcase its Cloud-Based Genomic Pipeline for Machine LearningJoel Wolter2021-10-05T13:21:36-04:00October 5, 2021|Read More
Immunis.AI Achieves Development Milestones and Additional FinancingJoel Wolter2021-09-29T17:14:51-04:00September 29, 2021|Read More
Immunis.AI Presents Discovery of Cancer-Related Signals in Circulating MonocytesJoel Wolter2021-09-21T17:55:29-04:00September 21, 2021|Read More
Immunis.AI Announces Additional Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Novel Methods and Technologies for Cancer DetectionJoel Wolter2021-12-14T13:00:12-05:00May 11, 2021|Read More
Immunis.AI Announces Two Patents Granted by the European Patent OfficeJoel Wolter2021-12-14T13:03:18-05:00July 14, 2020|Read More
Immunis.AI Announces Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Novel Methods and Technologies for Cancer Detection and PrognosisJoel Wolter2021-12-14T13:27:39-05:00April 21, 2020|Read More
Immunis.AI Announces Christopher Thibodeau as New President & Chief Executive OfficerJoel Wolter2021-09-30T18:56:53-04:00April 10, 2020|Read More
Immunis.AI to Present at the BIO CEO & Investor ConferenceJoel Wolter2020-02-06T20:07:34-05:00February 6, 2020|Read More
A OncoCell MDx, Now Immunis.AI, to Present at Biotech ShowcaseJoel Wolter2020-01-10T12:28:57-05:00January 10, 2020|Read More
